1: \begin{abstract}

2: For many rare diseases with no approved preventive interventions,  

3: promising interventions exist, yet it has been difficult to conduct a pivotal phase 3 trial that could provide direct evidence demonstrating a beneficial effect on the target disease outcome. 

4: When a promising putative surrogate endpoint(s) for the target outcome

5: is available, surrogate-based provisional approval of an intervention may be pursued.

6: We apply the Causal Roadmap rubric to define a surrogate endpoint based provisional approval causal roadmap, which combines observational study data that estimates the relationship between the putative surrogate and the target outcome, with a phase 3 surrogate endpoint study that collects the same data but 

7: is very under-powered to assess the treatment effect (TE) on the target outcome.

8: The objective is conservative estimation/inference for the TE with an estimated lower uncertainty bound that 

9: allows (through two bias functions) for an imperfect surrogate and imperfect transport of the conditional target outcome risk in the untreated between the observational and phase 3 studies. Two estimators of TE (plug-in, nonparametric efficient one-step) with corresponding inference procedures are developed. Finite-sample performance of the plug-in estimator is evaluated in two simulation studies, with R code provided.

10: The roadmap is illustrated with contemporary Group B Streptococcus vaccine development.

11: %{\color{purple} $\clubsuit$ PG 5-20-24:  The current plan is to post a version with simulations only for the plug-in approach for arXiv, and simulations for the nonparametric efficient approach will be added for the version for peer review.  $\clubsuit$}

12: \end{abstract}

13: